Page 32 - Read Online

Ossoliński et al. J Cancer Metastasis Treat 2019;5:1 I http://dx.doi.org/10.20517/2394-4722.2018.63 Page 11 of 12

Copyright
© The Author(s) 2019.

REFERENCES
1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. Screening and prostate-cancer mortality in a randomized European
study. N Engl J Med 2009;360:1320-8.
3. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, et al. Mortality results from the Göteborg randomised population-based prostate-
cancer screening trial. Lancet Oncol 2010;11:725-32.
4. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl
J Med 2009;360:1310-9.
5. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA
2014;311:1143-9.
6. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, et al. Detection of high-grade prostate cancer using a urinary molecular
biomarker-based risk score. Eur Urol 2016;70:740-8.
7. Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, et al. Cost-effectiveness of SelectMDx for prostate cancer in
four European countries: a comparative modeling study. Prostate Cancer Prostatic Dis 2018; doi:10.1038/s41391-018-0076-3.
8. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-9.
9. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell
Proteomics 2004;3:367-78.
10. Yang J, Zhu Y, Guo H, Wang X, Gao R, et al. Identifying serum biomarkers for ovarian cancer by screening with surface-enhanced laser
desorption/ionization mass spectrometry and the artificial neural network. Int J Gynecol Cancer 2013;23:667-72.
11. Wright GL Jr, Cazares LH, Leung SM, Nasim S, Adam BL, et al. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI)
mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate
Cancer Prostatic Dis 1999;2:264-76.
12. Ocak S, Chaurand P, Massion PP. Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 2009;6:159-70.
13. Martínez-Aguilar J, Chik J, Nicholson J, Semaan C, McKay MJ, et al. Quantitative mass spectrometry for colorectal cancer proteomics.
Proteomics Clin Appl 2013;7:42-54.
14. Wu B, Abbott T, Fishman D, McMurray W, Mor G, et al. Ovarian cancer classification based on mass spectrometry analysis of sera. Cancer
Inform 2007;2:123-32.
15. Nizioł J, Ossoliński K, Ossoliński T, Ossolińska A, Bonifay V, et al. Surface-transfer mass spectrometry imaging of renal tissue on gold
nanoparticle enhanced target. Anal Chem 2016;88:7365-71.
16. Whelan SA, He J, Lu M, Souda P, Saxton RE, et al. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in
proximal fluid. J Proteome Res 2012;11:5034-45.
17. Xue R, Dong L, Zhang S, Deng C, Liu T, et al. Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction
and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:1181-6.
18. Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, et al. Metabolomic profiling for the identification of novel diagnostic
markers in prostate cancer. Expert Rev Mol Diagn 2015;15:1211-24.
19. Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, et al. Improving the prediction of pathologic outcomes in patients undergoing
radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Res
2015;35:1017-23.
20. de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygård O, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation
to prostate cancer - a large nested case-control study within the JANUS cohort in Norway. Int J Cancer 2014;134:197-206.
21. de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Galasso G, et al. Body mass index was associated with upstaging and upgrading in
patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol 2015;33:201.
22. Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, et al. Low serum total testosterone level as a predictor of upstaging and
upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget 2017;8:18424-34.
23. Sekuła J, Nizioł J, Rode W, Ruman T. Gold nanoparticle-enhanced target (AuNPET) as universal solution for laser desorption/ionization
mass spectrometry analysis and imaging of low molecular weight compounds. Anal Chim Acta. 2015;875:61-72.
24. Cacciatore S, Zadra G, Bango C, Penney KL, Tyekucheva S, et al. Metabolic profiling in formalin-fixed and paraffin-embedded prostate
cancer tissues. Mol Cancer Res 2017;15:439-47.
25. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.
26. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
27. Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic
approach. Anticancer Res 2010;30:369-74.
28. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016;5:e189.
29. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of
clinically organ-confined prostate cancer. Urology 2001;57:108-11.
30. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral
androgen concentration of prostate tumors. PLoS One 2012;7:e30062.
31. Twiddy AL, Leon CG, Wasan KM. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 2011;28:423-37.
32. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate